Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Candel Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 12 | 20 | +8 |
| Shares | 4.88M | 6.95M | +2.07M (+42.3%) |
| Value | $52.9M | $54.4M | +$1.41M (+2.7%) |
New holders (10)
Institutions that held Candel Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Northpond Ventures, LLC | 1,935,215 | $15.1M | 5.30% |
| 683 Capital Management, LLC | 40,929 | $320.0K | 0.02% |
| Northern Trust Corp | 13,455 | $105.0K | 0.00% |
| Goldman Sachs Group Inc | 10,593 | $83.0K | 0.00% |
| D. E. Shaw & Co., Inc. | 10,122 | $79.0K | 0.00% |
| Morgan Stanley | 4,722 | $36.0K | 0.00% |
| JPMorgan Chase & Co | 2,529 | $20.0K | 0.00% |
| Bank of America Corp | 1,088 | $8.00K | 0.00% |
| Citigroup Inc | 866 | $7.00K | 0.00% |
| High Net Worth Advisory Group LLC | 300 | $2.00K | 0.00% |
Sold out (2)
Institutions that held Candel Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Caas Capital Management LP | 50,000 | $542.0K |
| Wells Fargo & Company | 1,054 | $12.0K |